The North America Plasma Fractionation Market was valued at $19715.6 Million in 2026 and projected to reach to $28658.5 Million by 2031, representing a compound annual growth rate of 7.8%. North America's plasma fractionation market is poised for significant expansion through 2031, supported by increasing diagnosis rates of immunodeficiency disorders, aging population demographics, and enhanced patient awareness.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America commands the largest share of the global plasma fractionation market, with the US alone representing USD 26,537.8 million in 2026, driven by sophisticated healthcare infrastructure and high treatment adoption rates.
Rising prevalence of primary immunodeficiency disorders and secondary immunodeficiency conditions across North America is fueling robust demand for immunoglobulin therapies, the largest product segment in the region.
North America's well-established regulatory framework, reimbursement policies, and presence of leading plasma collection centers support sustained market expansion and innovation in fractionation technologies.
The region is projected to grow from USD 19,715.6 million in 2026 to USD 28,658.5 million by 2031, representing a 7.8% CAGR, outpacing global average growth and reflecting increasing clinical adoption.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma | Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity |
|
|
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release | Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SCIG (Type) |
| Forecast Period | 2026-2030 |
| Growth Rate | CAGR of 7.6% from 2026 to 2030 |
| Largest Segment | THERAPEUTICS (Application) |
| Market Size Base Year (Billions) | ~USD 36.46 (2026) |
| Revenue Forecast (Billions) | ~USD 48.87 (2030) |
| Segments Covered | Product, Type, Application, Therapeutic Area, End User |
5 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| US | USD 26537.8 Million |
| Canada | USD 2120.7 Million |
North America's plasma fractionation market is valued at USD 19,715.6 million in 2026 and represents a significant portion of global plasma therapeutics demand.
North America's plasma fractionation market is forecast to reach USD 28,658.5 million by 2031, reflecting sustained growth in plasma-derived therapies.
North America's plasma fractionation market is growing at a compound annual growth rate of 7.8% from 2026 to 2031.
North America's market growth is driven by advanced healthcare infrastructure, aging population demographics, rising immunodeficiency disorders, and technological innovations in plasma fractionation.
North America leads in plasma fractionation due to strong regulatory frameworks, established plasma collection networks, significant biopharmaceutical investment, and high healthcare spending on specialized therapies.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..
The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report